DRL launches generic Pramipexole dihydrochloride in US market

August 27, 2015 IbisResearch Approvals, Formulations, New Launches 0

Dr Reddy’s Laboratories has launched generic Pramipexole dihydrochloride extended-release tablets for treatment of Parkinson’s disease in the US market. The company has launched the tablets in the strengths of 0.375 mg, 0.75 mg, 1.5 mg, 3 mg and 4.5 mg in the US market following approval from the USFDA. The DRL product is made available in bottle count sizes of 30

Company Profile : Dr Reddys Laboratories Ltd